Hemostatic Sealant Composition for Active Bleeding Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing hemostatic and sealant products are ineffective in controlling profuse or active bleeding, as they either wash away before setting or fail to form strong bonds with tissue proteins, necessitating the use of multiple products and techniques for effective hemostasis and wound sealing.
Innovation Solution
A combination of biocompatible hemostatic and sealant products, such as modified starch and PEG-based compositions, is applied sequentially or simultaneously to wounds to enhance gel formation and tissue bonding, providing rapid and effective hemostasis and sealing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If modified starch-based hemostatic composition is used, then hemostasis can be achieved for mild to moderate bleeding, but the gel formed is not strong enough to hold when blood flow is high due to inability to covalently bond to tissue proteins
Solution Approach 1:
The patent combines modified starch-based hemostatic composition with PEG-based sealant composition to create a composite material system. The modified starch provides rapid hemostatic action by absorbing blood and forming a gel, while the PEG component forms strong covalent bonds with tissue proteins through crosslinking reactions, creating a reinforced gel structure that can withstand high blood flow. This composite approach integrates the hemostatic functionality of starch with the adhesive strength of PEG.
Solution Approach 2:
The patent modifies the chemical parameters of the starch-based composition by incorporating PEG functional groups that can undergo crosslinking reactions. This changes the gel's mechanical properties from weak physical entanglement to strong covalent bonding, significantly enhancing the gel strength while maintaining the hemostatic functionality of the original starch-based material.
2Strength
If PEG-based sealant composition is used, then strong covalent bonds with tissue proteins can be formed, but gel formation takes too long and blood washes away the composition before it sets
Solution Approach 1:
The modified starch-based hemostatic composition acts first to rapidly absorb blood and form an initial gel structure at the wound site. This preliminary action creates a matrix that retains the PEG-based sealant composition in place, preventing it from being washed away by blood flow. Subsequently, the PEG crosslinking reaction proceeds to form strong covalent bonds, achieving both rapid initial hemostasis and long-term adhesive strength.
Solution Approach 2:
The modified starch-based composition serves as an intermediary that bridges the gap between immediate hemostatic needs and long-term sealant functionality. It provides rapid blood absorption and initial gel formation, creating a stable environment that allows the slower PEG crosslinking reaction to proceed effectively without being disrupted by blood flow.
3Reliability
If both hemostat and sealant are used separately, then comprehensive hemostasis and sealing can be achieved, but the treatment process becomes complex and time-consuming
Solution Approach 1:
The patent merges the hemostat and sealant into a single combined composition containing both modified starch-based hemostatic agents and PEG-based sealant components. This unified formulation allows simultaneous delivery of both functionalities - rapid blood absorption and gel formation from the starch component, plus strong covalent bonding from the PEG component - eliminating the need for separate application steps and simplifying the treatment process while maintaining comprehensive hemostasis and sealing effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination achieves immediate and sustained hemostasis, wound sealing, reduces exudation, promotes healing, and prevents infection, even in cases of severe bleeding, with faster application and convenience for medical professionals.
Implementation Method 1
forming covalent bonds with tissue proteins to achieve rapid and effective hemostasis and wound sealing
Implementation Method 2
Tissue sealants function by solidifying or gelatinizing (gel forming) and/or by interacting with blood to trigger clot formation
Data Source
AI summary
The present specification describes a biocompatible hemostatic composition and a biocompatible tissue sealant, which when used in combination provides a safe and effective method of achieving hemostasis. The biocompatible composition and sealant may be applied either on a surface of the patient's body, or inside the body cavity. The combination may be used to control bleeding from external wounds and internal injuries, as well as to minimize bleeding during surgical procedures.